These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 37675346)

  • 1. What have we learned from a case of convalescent plasma treatment in a two-time kidney transplant recipient COVID-19 patient? A case report from the perspective of viral load evolution and immune response.
    Aldunate F; Fajardo A; Ibañez N; Rammauro F; Daghero H; Arce R; Ferla D; Pereira-Gomez M; Salazar C; Iraola G; Pritsch O; Hurtado J; Tenzi J; Bollati-Fogolín M; Bianchi S; Nin N; Moratorio G; Moreno P
    Front Nephrol; 2023; 3():1132763. PubMed ID: 37675346
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment of 5 Critically Ill Patients With COVID-19 With Convalescent Plasma.
    Shen C; Wang Z; Zhao F; Yang Y; Li J; Yuan J; Wang F; Li D; Yang M; Xing L; Wei J; Xiao H; Yang Y; Qu J; Qing L; Chen L; Xu Z; Peng L; Li Y; Zheng H; Chen F; Huang K; Jiang Y; Liu D; Zhang Z; Liu Y; Liu L
    JAMA; 2020 Apr; 323(16):1582-1589. PubMed ID: 32219428
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Convalescent plasma or hyperimmune immunoglobulin for people with COVID-19: a rapid review.
    Valk SJ; Piechotta V; Chai KL; Doree C; Monsef I; Wood EM; Lamikanra A; Kimber C; McQuilten Z; So-Osman C; Estcourt LJ; Skoetz N
    Cochrane Database Syst Rev; 2020 May; 5(5):CD013600. PubMed ID: 32406927
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluating the efficacy and safety of human anti-SARS-CoV-2 convalescent plasma in severely ill adults with COVID-19: A structured summary of a study protocol for a randomized controlled trial.
    Eckhardt CM; Cummings MJ; Rajagopalan KN; Borden S; Bitan ZC; Wolf A; Kantor A; Briese T; Meyer BJ; Jacobson SD; Scotto D; Mishra N; Philip NM; Stotler BA; Schwartz J; Shaz B; Spitalnik SL; Eisenberger A; Hod EA; Justman J; Cheung K; Lipkin WI; O'Donnell MR
    Trials; 2020 Jun; 21(1):499. PubMed ID: 32513308
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Randomized Open label Phase-II Clinical Trial with or without Infusion of Plasma from Subjects after Convalescence of SARS-CoV-2 Infection in High-Risk Patients with Confirmed Severe SARS-CoV-2 Disease (RECOVER): A structured summary of a study protocol for a randomised controlled trial.
    Janssen M; Schäkel U; Djuka Fokou C; Krisam J; Stermann J; Kriegsmann K; Haberbosch I; Novotny JP; Weber S; Vehreschild M; Bornhäuser M; Bullinger L; Schmitt M; Liebregts T; Dreger P; Lorenz HM; Plaszczyca A; Bartenschlager R; Müller B; Kräusslich HG; Halama N; Jäger D; Schlenk RF; Leo A; Meuer S; Weigand MA; Motsch J; Merle U; Denkinger CM; Müller-Tidow C
    Trials; 2020 Oct; 21(1):828. PubMed ID: 33023671
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A 63-Year-Old Woman with SARS-CoV-2 Infection, Who Developed Severe COVID-19 Pneumonia and Was Supported with Convalescent Plasma Therapy.
    Moniuszko-Malinowska A; Czupryna P; Boczkowska-Radziwon B; Wasiluk T; Borawski K; Dunaj J; Bujno M; Radziwon P; Rutkowski K; Pancewicz S
    Am J Case Rep; 2020 Sep; 21():e927662. PubMed ID: 32991573
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Reconvalescent plasma/camostat mesylate in early SARS-CoV-2 Q-PCR positive high-risk individuals (RES-Q-HR): a structured summary of a study protocol for a randomized controlled trial.
    Keitel V; Jensen B; Feldt T; Fischer JC; Bode JG; Matuschek C; Bölke E; Budach W; Plettenberg C; Scheckenbach K; Kindgen-Milles D; Timm J; Müller L; Kolbe H; Stöhr A; Calles C; Hippe A; Verde P; Spinner CD; Schneider J; Wolf T; Kern WV; Nattermann J; Zoufaly A; Ohmann C; Luedde T;
    Trials; 2021 May; 22(1):343. PubMed ID: 34001215
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Randomized clinical trial to evaluate safety and efficacy of convalescent plasma use among hospitalized patients with COVID-19 (PERUCONPLASMA): a structured summary of a study protocol for a randomized controlled trial.
    Soto A; Krapp F; Vargas A; Cabrejos L; Argumanis E; García PL; Altamirano K; Montes M; Chacón-Uscamaita PR; García PJ
    Trials; 2021 May; 22(1):342. PubMed ID: 34001174
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Emergence of Multiple SARS-CoV-2 Antibody Escape Variants in an Immunocompromised Host Undergoing Convalescent Plasma Treatment.
    Chen L; Zody MC; Di Germanio C; Martinelli R; Mediavilla JR; Cunningham MH; Composto K; Chow KF; Kordalewska M; Corvelo A; Oschwald DM; Fennessey S; Zetkulic M; Dar S; Kramer Y; Mathema B; Germer S; Stone M; Simmons G; Busch MP; Maniatis T; Perlin DS; Kreiswirth BN
    mSphere; 2021 Aug; 6(4):e0048021. PubMed ID: 34431691
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A possible dose-response equation: Viral load after plasma infusion in COVID-19 patients and anti-SARS-CoV-2 antibody titers in convalescent plasma.
    He R; Wang J; Wang Z; Liu Y; Xu H; Zhang X; Deng E; Yin Y; Ji X; Guan X; Ren Q; Wu C; Chen Y; Li L; Zhang W; Liu Z
    Transfus Med; 2022 Apr; 32(2):162-167. PubMed ID: 35088494
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Severe Acute Respiratory Syndrome Coronavirus 2 Neutralizing Antibody Titers in Convalescent Plasma and Recipients in New Mexico: An Open Treatment Study in Patients With Coronavirus Disease 2019.
    Bradfute SB; Hurwitz I; Yingling AV; Ye C; Cheng Q; Noonan TP; Raval JS; Sosa NR; Mertz GJ; Perkins DJ; Harkins MS
    J Infect Dis; 2020 Oct; 222(10):1620-1628. PubMed ID: 32779705
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Successful Recovery of a Critically Ill COVID-19 Patient, Following the Combination of Therapeutic Plasma Exchange and Convalescent Plasma Transfusion: A Case Report.
    Novacescu AN; Duma G; Sandesc D; Sorescu T; Licker M
    Medicina (Kaunas); 2022 Aug; 58(8):. PubMed ID: 36013555
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Feasibility of Convalescent Plasma Therapy in Kidney Transplant Recipients With Severe COVID-19: A Single-Center Prospective Cohort Study.
    Gupta A; Kute VB; Patel HV; Engineer DP; Banerjee S; Modi PR; Rizvi SJ; Mishra VV; Patel AH; Navadiya V
    Exp Clin Transplant; 2021 Apr; 19(4):304-309. PubMed ID: 33605203
    [TBL] [Abstract][Full Text] [Related]  

  • 14. "Early transfusion of convalescent plasma in older patients with COVID-19 to prevent disease progression: A structured summary of a study protocol for a randomised controlled trial".
    Teofili L; Landolfi R; Cingolani A; Antinori A; Vecchiet J; Sanguinetti M; Gasbarrini A; Pasciuto T; Orlando N; Lamonica S
    Trials; 2020 Oct; 21(1):875. PubMed ID: 33092632
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment with convalescent plasma for COVID-19 patients in Wuhan, China.
    Ye M; Fu D; Ren Y; Wang F; Wang D; Zhang F; Xia X; Lv T
    J Med Virol; 2020 Oct; 92(10):1890-1901. PubMed ID: 32293713
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of Convalescent Plasma Therapy on Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Antibody Profile in Coronavirus Disease 2019 (COVID-19) Patients.
    Tang J; Grubbs G; Lee Y; Golding H; Khurana S
    Clin Infect Dis; 2022 Jan; 74(2):327-334. PubMed ID: 33861337
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Convalescent plasma or hyperimmune immunoglobulin for people with COVID-19: a living systematic review.
    Chai KL; Valk SJ; Piechotta V; Kimber C; Monsef I; Doree C; Wood EM; Lamikanra AA; Roberts DJ; McQuilten Z; So-Osman C; Estcourt LJ; Skoetz N
    Cochrane Database Syst Rev; 2020 Oct; 10():CD013600. PubMed ID: 33044747
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety and efficacy of convalescent plasma for severe COVID-19: a randomized, single blinded, parallel, controlled clinical study.
    Rojas M; Rodríguez Y; Hernández JC; Díaz-Coronado JC; Vergara JAD; Vélez VP; Mancilla JP; Araujo I; Yepes JT; Ricaurte OB; Pardo-Oviedo JM; Monsalve DM; Acosta-Ampudia Y; Ramírez-Santana C; García PG; Landinez LA; Correales LD; Grass JS; Pérez CR; López GS; Mateus N; Mancera L; Devia RR; Orjuela JE; Parra-Moreno CR; Buitrago AA; Ordoñez IE; Osorio CF; Ballesteros N; Patiño LH; Castañeda S; Muñoz M; Ramírez JD; Bastard P; Gervais A; Bizien L; Casanova JL; Camacho B; Gallo JE; Gómez O; Rojas-Villarraga A; Pérez CE; Manrique R; Mantilla RD; Anaya JM
    BMC Infect Dis; 2022 Jun; 22(1):575. PubMed ID: 35761219
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Convalescent Plasma for the Treatment of Severe COVID-19 Infection in Cancer Patients.
    Tremblay D; Seah C; Schneider T; Bhalla S; Feld J; Naymagon L; Wang B; Patel V; Jun T; Jandl T; Rahman F; Liu STH; Aberg JA; Bouvier N;
    Cancer Med; 2020 Nov; 9(22):8571-8578. PubMed ID: 32945149
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy of convalescent plasma therapy for COVID-19 in Japan: An open-label, randomized, controlled trial.
    Saito S; Kutsuna S; Akifumi I; Hase R; Oda R; Terada J; Shimizu Y; Uemura Y; Takamatsu Y; Yasuhara A; Shiratori K; Satake M; Sakamoto N; Miyazaki Y; Shimizu H; Togano T; Matsunaga A; Okuma K; Hamaguchi I; Fujisawa K; Nagashima M; Ashida S; Terada M; Kimura A; Morioka S; Matsubayashi K; Tsuno NH; Kojima M; Kuramitsu M; Tezuka K; Ikebe E; Ishizaka Y; Kenji M; Hangaishi A; Mikami A; Sugiura W; Ohmagari N; Mitsuya H
    J Infect Chemother; 2023 Sep; 29(9):869-874. PubMed ID: 37178973
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.